Literature DB >> 25448228

Novel opportunities for next-generation probiotics targeting metabolic syndrome.

Patrice D Cani1, Matthias Van Hul2.   

Abstract

Various studies have described the beneficial effects of specific bacteria on the characteristics of metabolic syndrome. Intestinal microbiota might therefore represent a modifiable trait for translational intervention to improve the metabolic profiles of obese and type 2 diabetic patients. However, identifying potential probiotic strains that can effectively colonize the gastrointestinal tract and significantly affect host metabolism has been challenging. This review aims to summarize the notable advances and contributions in the field that may prove useful for identifying next-generation probiotics that target metabolic syndrome and its related disorders.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25448228     DOI： 10.1016/j.copbio.2014.10.006

Source DB:  PubMed          Journal:  Curr Opin Biotechnol        ISSN： 0958-1669            Impact factor:   9.740


  48 in total

1.  Lactobacillus plantarum bacteriocin is associated with intestinal and systemic improvements in diet-induced obese mice and maintains epithelial barrier integrity in vitro.

Authors:  Dustin D Heeney; Zhengyuan Zhai; Zach Bendiks; Javad Barouei; Alice Martinic; Carolyn Slupsky; Maria L Marco
Journal:  Gut Microbes       Date:  2018-11-08

Review 2.  Gut microbiota in human metabolic health and disease.

Authors:  Yong Fan; Oluf Pedersen
Journal:  Nat Rev Microbiol       Date:  2020-09-04       Impact factor: 60.633

Review 3.  Oxidative stress in metabolic diseases: current scenario and therapeutic relevance.

Authors:  Satish K Raut; Madhu Khullar
Journal:  Mol Cell Biochem       Date:  2022-06-28       Impact factor: 3.396

4.  Targeting Kupffer cells in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why and how?

Authors:  Nicolas Lanthier
Journal:  World J Hepatol       Date:  2015-09-08

5.  Probiotics Supplemented with Omega-3 Fatty Acids are More Effective for Hepatic Steatosis Reduction in an Animal Model of Obesity.

Authors:  Nazarii Kobyliak; Tetyana Falalyeyeva; Petro Bodnar; Tetyana Beregova
Journal:  Probiotics Antimicrob Proteins       Date:  2017-06       Impact factor: 4.609

Review 6.  Resistant starches for the management of metabolic diseases.

Authors:  Laure B Bindels; Jens Walter; Amanda E Ramer-Tait
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2015-11       Impact factor: 4.294

Review 7.  Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies.

Authors:  Hamed Ebrahimzadeh Leylabadlo; Reza Ghotaslou; Hossein Samadi Kafil; Mohammad Mehdi Feizabadi; Seyed Yaghoub Moaddab; Safar Farajnia; Elham Sheykhsaran; Sarvin Sanaie; Dariush Shanehbandi; Hossein Bannazadeh Baghi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-12-11       Impact factor: 3.267

8.  Strain-level analysis of gut-resident pro-inflammatory viridans group Streptococci suppressed by long-term cotrimoxazole prophylaxis among HIV-positive children in Zimbabwe.

Authors:  Ethan K Gough; Claire D Bourke; Chipo Berejena; Annie Shonhai; Mutsa Bwakura-Dangarembizi; Andrew J Prendergast; Amee R Manges
Journal:  Gut Microbes       Date:  2020-02-05

9.  New insights on strain-specific impacts of probiotics on insulin resistance: evidence from animal study.

Authors:  Nazarii Kobyliak; Tetyana Falalyeyeva; Olena Tsyryuk; Majid Eslami; Dmytro Kyriienko; Tetyana Beregova; Liudmila Ostapchenko
Journal:  J Diabetes Metab Disord       Date:  2020-02-16

10.  Evaluation of GABA Production and Probiotic Activities of Enterococcus faecium BS5.

Authors:  Sabna Bs; Bency Thankappan; Ramasamy Mahendran; Gayathri Muthusamy; Daniel Raja Femil Selta; Jayaraman Angayarkanni
Journal:  Probiotics Antimicrob Proteins       Date:  2021-03-10       Impact factor: 4.609
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.